LEAVE Safe With DOACs

Stroke Clinical Trial

Official title: Leveraging Evidence-based Practices for Ambulatory VTE and Other Patients to be Safe With Direct Oral Anticoagulants: LEAVE Safe With DOACs

Status Completed

Clinical Trial Summary

Given the risks associated with direct oral anticoagulants (DOACs) and the lack of defined pathways for patients prescribed this class of medications, the study intervention has the potential for an enormous impact in preventing medication errors and improving the quality of care transition, patient knowledge, and adherence with DOAC therapy.

Clinical Trial Description

Patients first treated with direct oral anticoagulants (DOACs) in an ambulatory setting are at an elevated risk for adverse drug events (ADEs) or potential ADEs from medication errors. An intervention that integrates clinical pharmacists, a pharmacy technician, and follows a checklist published by experts at the Anticoagulation Forum can prevent adverse outcomes. The Investigators propose research on the effectiveness, implementation, and dissemination for a care transition intervention that follows the checklist which includes evaluation for appropriateness of DOAC use, assistance with drug procurement, telephone access to an anticoagulation expert, and other best practice recommendations. ;

Related Conditions & MeSH terms

• Atrial Fibrillation
• Bleeding
• Cardiovascular Diseases
• Stroke
• Thromboembolism
• Venous Thromboembolism

• NCT number: NCT04068727
• Study type: Interventional
• Source: University of Massachusetts, Worcester
• Status: Completed
• Phase: N/A
• Start date: December 2, 2019
• Completion date: September 14, 2022